Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04927780 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Study acronym: PREOPANC-3
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Feb 2026 to Jan 2027 Trial status: Recruiting to Active, Not Recruiting · Study sites: 22 to 21v14 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 22 to 21
  2. Re-verified, no change to tracked fieldsv13
  3. Publications: details revised at 1 of 1 entryv12
  4. Study sites: 20 to 22v11
  5. Study sites: 17 to 20v10
Show 8 earlier versionsHide 8 earlier versions
  1. Study sites: 15 to 17v9
  2. Site details revised at 1 of 15 sitesv8
  3. Site details revised at 2 of 15 sitesv7
  4. Site details revised at 2 of 15 sitesv6
  5. Site details revised at 6 of 15 sitesv5
  6. Site details revised at 1 of 15 sitesv4
  7. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Aug 2021 to Sep 7, 2021 · Site details revised at 15 of 15 sitesv3 Show 2 more changesShow less
    • Start date changed from estimate of Aug 2021 to Sep 7, 2021
    • Site details revised at 15 of 15 sites
  8. Start date: Jul 2021 to Aug 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery followed by 12 cycles of adjuvant mFOLFIRINOX (arm 2). The primary objective of the trial is to determine whether perioperative mFOLFIRINOX improves overall survival compared with adjuvant mFOLFIRINOX in patients with resectable pancreatic cancer.
Trial Details
NCT Number NCT04927780
Lead Sponsor Erasmus Medical Center
Collaborators: Dutch Pancreatic Cancer Group, Dutch Cancer Society
Conditions Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
Enrollment 378 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov